Newton Golf Company (NASDAQ: NWTG) Tees Up Innovation for the ‘Sport's New Face'
To view the full article, visit https://ibn.fm/yRgKg
About Newton Golf Company Inc.
Newton Golf harnesses the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, the company's rebranding reflects its commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of its design process, Newton Golf creates precision-engineered golf clubs that deliver unmatched stability, control, and performance. The company's mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.
For more information, visit the company's website at www.NewtonGolfIR.com.
About InvestorWire
InvestorWire ('IW') is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
25 minutes ago
- CBC
How should Canada respond to U.S. tariff increase?
As U.S. President Donald Trump bumps up import tariffs on non-CUSMA-compliant Canadian goods to 35 per cent, the Power & Politics panel of party insiders discusses how Canada should respond and whether there should be an expiration date on negotiations.
Globe and Mail
27 minutes ago
- Globe and Mail
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the 'Company') (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Aug. 1, 2025, the Compensation Committee of the Company's Board of Directors (the 'Compensation Committee') granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 39,000 shares of common stock to 5 new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $10.59 per share, the Company's closing sales price on Aug. 1, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company's 2024 Inducement Plan and the terms and conditions of an applicable stock option agreement covering the grant. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit
Globe and Mail
27 minutes ago
- Globe and Mail
Baytex Energy Reports Strong Q2 2025 Results and Announces October Dividend
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Baytex Energy ( (TSE:BTE)) has provided an announcement. Baytex Energy Corp. reported solid second-quarter results for 2025, highlighted by record well performance in the Pembina Duvernay region and continued debt reduction. The company also announced a quarterly dividend for October 2025, reflecting its strong financial position and commitment to returning value to shareholders. The most recent analyst rating on (TSE:BTE) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on Baytex Energy stock, see the TSE:BTE Stock Forecast page. Spark's Take on TSE:BTE Stock According to Spark, TipRanks' AI Analyst, TSE:BTE is a Outperform. Baytex Energy's strong financial performance and positive technical indicators are the primary drivers of its solid stock score. Despite challenges from commodity prices, the company's strategic debt reduction and cash flow focus provide stability. To see Spark's full report on TSE:BTE stock, click here. More about Baytex Energy Baytex Energy Corp. is a Canadian energy company primarily involved in the exploration, development, and production of oil and natural gas. The company focuses on operations in key resource plays in North America, including the Pembina Duvernay region. Average Trading Volume: 6,145,983 Technical Sentiment Signal: Sell Current Market Cap: C$2.32B See more insights into BTE stock on TipRanks' Stock Analysis page.
